Proteomic analysis of A549 lung cancer cells treated with cisplatin and metformin

• Grant number: 17/04269-5
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: July 01, 2017
• End date: June 30, 2018
• Field of knowledge: Health Sciences - Nutrition - Nutrition Biochemistry
• Principal Investigator: Fernando Moreira Simabuco
• Grantee: Ana Paula Morelli
• Host Institution: Faculdade de Ciências Aplicadas (FCA). Universidade Estadual de Campinas (UNICAMP). Limeira , SP, Brazil
• Associated research grant: 12/13558-7 - Molecular characterization of S6Ks in obesity and its associated diseases, AP.JP

Abstract

The therapeutic combination of cisplatin and metformin has been shown very effective in cancer treatment, especially in lung cancer. Metformin, a hypoglycemic drug frequently used for the treatment of Type 2 Diabetes Mellitus, has shown over the years a reduction in cancer incidence and mortality and therefore has been studied as a possible treatment against that disease. Several studies have demonstrated an effective combination of metformin and several other chemotherapeutics, including cisplatin. Nevertheless, the molecular mechanisms involving an action between cisplatin and metformin are still unclear. The present study aim to realize a proteomic analysis with lung cancer cells A549 submitted to this therapeutic combination, identifying changes in the expression of proteins by the SILAC (Stable Isotope Labeling by Amino acids in Cell culture) technique. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

MORELLI, ANA PAULA; TORTELLI, THARCISIO CITRANGULO JR JR; BETIM PAVAN, ISADORA CAROLINA; SILVA, FERNANDO RIBACK; GRANATO, DANIELA CAMPOS; PERUCA, GUILHERME FRANCISCO; PAULETTI, BIANCA ALVES; DOMINGUES, ROMENIA RAMOS; NEVES BEZERRA, ROSANGELA MARIA; DE MOURA, LEANDRO PEREIRA; et al. Metformin impairs cisplatin resistance effects in A549 lung cancer cells through mTOR signaling and other metabolic pathways. International Journal of Oncology, v. 58, n. 6, JUN 2021. (16/02483-7, 19/00607-9, 15/22814-5, 17/04269-5, 15/16601-9, 18/14818-9, 16/06457-0, 12/13558-7)